Dyslipdemia induced by chronic low dose co-exposure to lead, cadmium and manganese in rats: the role of oxidative stress

NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome-mediated pyroptosis is a crucial event in the preeclamptic pathogenesis, tightly linked with the uteroplacental TLR4/NF-κB signaling. Trophoblastic glycometabolism reprogramming has now been noticed in the preeclampsia pathogenesis, plausibly modulated by the TLR4/NF-κB signaling as well. Intriguingly, cellular pyroptosis and metabolic phenotypes may be inextricably linked and interacted. Metformin (MET), a widely accepted NF-κB signaling inhibitor, may have therapeutic potential in preeclampsia while the underlying mechanisms remain unclear. Herein, we investigated the role of MET on trophoblastic pyroptosis and its relevant metabolism reprogramming. The safety of pharmacologic MET concentration to trophoblasts was verified at first, which had no adverse effects on trophoblastic viability. Pharmacological MET concentration suppressed NLRP3 inflammasome-induced pyroptosis partly through inhibiting the TLR4/NF-κB signaling in preeclamptic trophoblast models induced via low-dose lipopolysaccharide. Besides, MET corrected the glycometabolic reprogramming and oxidative stress partly via suppressing the TLR4/NF-κB signaling and blocking transcription factor NF-κB1 binding on the promoter PFKFB3, a potent glycolytic accelerator. Furthermore, PFKFB3 can also enhance the NF-κB signaling, reduce NLRP3 ubiquitination, and aggravate pyroptosis. However, MET suppressed pyroptosis partly via inhibiting PFKFB3 as well. These results provided that the TLR4/NF-κB/PFKFB3 pathway may be a novel link between metabolism reprogramming and NLRP3 inflammasome-induced pyroptosis in trophoblasts. Further, MET alleviates the NLRP3 inflammasome-induced pyroptosis, which partly relies on the regulation of TLR4/NF-κB/PFKFB3-dependent glycometabolism reprogramming and redox disorders. Hence, our results provide novel insights into the pathogenesis of preeclampsia and propose MET as a potential therapy.

Download Full-text

Possible Protective Effects of high- versus low- dose of lutein in combination with irinotecan on Liver of Rats: Role of Oxidative Stress and Apoptosis

Indian Journal of Forensic Medicine & Toxicology ◽

10.37506/ijfmt.v15i1.13767 ◽

2021 ◽

Keyword(s):

Oxidative Stress ◽

Low Dose ◽

Protective Effects

Download Full-text

Role of atrial natriuretic peptide in controlling diabetic nephropathy in rats

Journal of Basic and Clinical Physiology and Pharmacology ◽

10.1515/jbcpp-2017-0146 ◽

2018 ◽

Vol 29 (5) ◽

pp. 499-505 ◽

Cited By ~ 2

Author(s):

Lakhwinder Singh ◽

Atul Arya ◽

Sumeet Gupta

Keyword(s):

Oxidative Stress ◽

Nitric Oxide ◽

Diabetic Nephropathy ◽

Low Dose ◽

Thiobarbituric Acid ◽

Urine Concentration ◽

High Dose ◽

Nitric Oxide Level ◽

Nitrite Nitrate

Abstract Background Diabetes is a downregulator of atrial natriuretic peptide (ANP), resulting in reduced nitric oxide level and low expression of endothelial nitric oxide synthase by which nitric oxide level get reduced. In the present study, we examined the role of ANP in reduced nitric oxide level, which may be responsible in controlling diabetic nephropathy in rats. Methods Serum nitrite/nitrate ratio, blood urea nitrogen, protein in urine, urinary output, serum creatinine, serum cholesterol, kidney weight, kidney hypertrophy, renal cortical collagen content, thiobarbituric acid level, and antioxidant enzymatic activities were assessed. Results Treatment with lisinopril (1 mg/kg) significantly attenuated diabetes-induced elevated glucose level, cholesterol level, and protein in urine concentration. Whereas ANP at low dose (5 μg/kg) has no effect on elevated markers of diabetic nephropathy, treatment with intermediate (10 μg/kg) and high-dose ANP (20 μg/kg) significantly attenuated the diabetes-induced increased blood urea nitrogen, protein in urine, urinary output, creatinine, cholesterol, kidney weight, kidney hypertrophy, renal collagen content, and thiobarbituric acid level and reduced endogenous antioxidant enzymatic activities. High dose of ANP was more effective in attenuating the diabetes-induced nephropathy, renal oxidative stress, and antioxidant enzyme activity as compared with the treatment with low-dose ANP (5 μg/kg), intermediate-dose ANP (10 μg/kg), or lisinopril (1 mg/kg, employed as standard agent). Administration of erythro-9-(2-hydroxy-3-nonyl)adenine, a phosphodiesterase-2 inhibitor (3 mg/kg), in combination with high-dose ANP significantly attenuated high-dose ANP induced ameliorative effects in diabetic nephropathy. Conclusions Taken together, these results indicate that diabetes-induced oxidative stress and lipid alterations may be responsible for the induction of nephropathy in diabetic rats. ANP at intermediate and high doses have prevented the development of diabetes-induced nephropathy by reducing the cholesterol level, protein in urine concentration, and renal oxidative stress and by increasing the nitrite/nitrate ratio, certainly providing the direct nephroprotective action.

Download Full-text

Abstract 056: Isolevuglandin-modified Phosphatidylethanolamines Generate Hypertension and Vascular Dysfunction in Mice

Hypertension ◽

10.1161/hyp.68.suppl_1.056 ◽

2016 ◽

Vol 68 (suppl_1) ◽

Author(s):

Arvind K Pandey ◽

Hana A Itani ◽

Liang Xiao ◽

Annet Kirabo ◽

Sergey Dikalov ◽

...

Keyword(s):

Oxidative Stress ◽

Immune Cells ◽

Protein Modification ◽

Low Dose ◽

Vascular Dysfunction ◽

Ang Ii ◽

Vascular Relaxation ◽

Wild Type ◽

Baseline Blood Pressure

Oxidative stress is an important contributor to hypertension. Our group has shown that oxidative stress generates isolevuglandins (isoLG) that modify proteins and that these isoLG-modified proteins seem to act as neoantigens to promote hypertension. In addition to proteins, isoLG can also modify phosphatidylethanolamines (PEs). IsoLG-modified PE (IsoLG-PE) can in turn activate immune cells via reactions with toll-like receptors and downstream pathways including NFκB. The role of isoLG-PE in hypertension has not yet been defined. We have previously shown that the enzyme N-acyl-phosphatidylethanolamine-phospholipase D (NAPE-PLD) cleaves isoLG-PE, and mice lacking this enzyme have elevated cellular levels of isoLG-PE. To assess whether loss of NAPE-PLD and resulting increase in isoLG-PE contributes to hypertension, we infused wild type (WT) and NAPE-PLD -/- mice with low dose Ang II. We found baseline blood pressure was elevated in NAPE-PLD -/- mice compared to WT mice (128 ± 3 vs 111 ± 2 mmHg, p = 0.005) and that the increase in BP to low dose Ang II infusion (140 ng/kg/min) was augmented in NAPE-PLD -/- compared to WT mice (146 ± 9 vs 127 ± 4 mmHg, p=0.045). Endothelium-dependent vascular relaxation of the mesenteric arterioles to acetylcholine was impaired in NAPE-PLD -/- compared to WT mice (maximum relaxation of 43% ± 6% vs 53% ± 5%, p= 0.004), but endothelium-independent responses to sodium nitroprusside were similar in both groups (82% ± 2% in NAPE-PLD -/- mice vs 81% ± 4% in WT mice). Aortic adventitial collagen content by planimetry was likewise increased in NAPE-PLD -/- versus WT mice following low-dose Ang II. These studies in mice lacking NAPE-PLD suggest that in addition to exerting its effects via protein modification to form neo-antigens, the reaction of isoLG with PE and related phospholipids can augment hypertension, alter endothelium-dependent vasodilatation and promote vascular fibrosis.

Download Full-text